Loading…
Based on limited metadata, the FDA issued a warning letter to MyRxAffiliate Program on October 9, 2018, regarding drug-related violations. Without access to the full letter text or specific subject line, the precise nature of the violations cannot be determined from the available information. The warning letter was issued under FDA's drug regulatory authority, though the specific issuing office is not identified in the metadata provided. Additional documentation would be needed to identify the specific compliance issues cited.